HUP9802062A2 - Gyors vizsgálati eljárás funkciónálisan inaktív gének mennyiségének meghatározására génterápiás vektorkészítményben - Google Patents

Gyors vizsgálati eljárás funkciónálisan inaktív gének mennyiségének meghatározására génterápiás vektorkészítményben

Info

Publication number
HUP9802062A2
HUP9802062A2 HU9802062A HUP9802062A HUP9802062A2 HU P9802062 A2 HUP9802062 A2 HU P9802062A2 HU 9802062 A HU9802062 A HU 9802062A HU P9802062 A HUP9802062 A HU P9802062A HU P9802062 A2 HUP9802062 A2 HU P9802062A2
Authority
HU
Hungary
Prior art keywords
gene
determining
amount
gene therapy
therapy vector
Prior art date
Application number
HU9802062A
Other languages
English (en)
Inventor
Laurent Bracco
Jack Roth
Bruno Tocque
Wei-Wei Zhang
Original Assignee
Board Of Regents The University Of Texas System
Rhone-Poulenc Rorer S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Regents The University Of Texas System, Rhone-Poulenc Rorer S.A. filed Critical Board Of Regents The University Of Texas System
Publication of HUP9802062A2 publication Critical patent/HUP9802062A2/hu
Publication of HUP9802062A3 publication Critical patent/HUP9802062A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A találmány tárgya őlyan mérési eljárás, amely egy terápiás géntkódőló vektőrkészletben a defektív vektőrők százalékős mennyiségénekbecslésére alkalmazható. Közelebbről, a találmány tárgyát fűnkcióvalnem rendelkező p53-gént tartalmazó adenővírűs százalékős mennyiségénekbecslésére alkalmas eljárás képezi őlyan denővírűsvektőr-készletben,amely a klinikai génterápiában alkalmazőtt vad típűsú p53-génttartalmazza. A találmány szerinti megőldás alkalmas a génterápiábanrekőmbináns ágensek minőség-ellenőrzésére. ŕ
HU9802062A 1995-02-17 1996-02-14 A rapid test for determining the amount of functionally inactive gene in a gene therapy vector preparation HUP9802062A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/390,887 US5637456A (en) 1995-02-17 1995-02-17 Rapid test for determining the amount of functionally inactive gene in a gene therapy vector preparation

Publications (2)

Publication Number Publication Date
HUP9802062A2 true HUP9802062A2 (hu) 1998-12-28
HUP9802062A3 HUP9802062A3 (en) 2001-08-28

Family

ID=23544364

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9802062A HUP9802062A3 (en) 1995-02-17 1996-02-14 A rapid test for determining the amount of functionally inactive gene in a gene therapy vector preparation

Country Status (17)

Country Link
US (1) US5637456A (hu)
EP (1) EP0811077B1 (hu)
JP (1) JPH11500012A (hu)
KR (1) KR19980702312A (hu)
AT (1) ATE283371T1 (hu)
AU (1) AU700427B2 (hu)
BR (1) BR9607613A (hu)
CA (1) CA2213116A1 (hu)
CZ (1) CZ257597A3 (hu)
DE (1) DE69633913D1 (hu)
HU (1) HUP9802062A3 (hu)
NO (1) NO973770L (hu)
NZ (1) NZ303040A (hu)
PL (1) PL182817B1 (hu)
SK (1) SK283027B6 (hu)
UA (1) UA45492C2 (hu)
WO (1) WO1996025515A1 (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2760009A1 (fr) * 1997-02-27 1998-08-28 Atochem Elf Sa Procede de fabrication d'acide acrylique a partir de l'acroleine par reaction redox et l'utilisation d'une composition solide d'oxydes mixtes comme systeme redox dans ladite reaction
US7691370B2 (en) 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
AU6175801A (en) * 2000-07-19 2002-02-05 Univ California Methods for therapy of neurodegenerative disease of the brain
FR2821624B1 (fr) * 2001-03-01 2004-01-02 Sod Conseils Rech Applic Nouveau polynucleotide utilisable pour moduler la proliferation des cellules cancereuses
US6908560B2 (en) * 2003-03-12 2005-06-21 Basin Water, Inc. Zero brine, zero rinse water process for treatment of contaminated drinking water for removal of arsenic
US8048999B2 (en) * 2005-12-13 2011-11-01 Kyoto University Nuclear reprogramming factor
US20090227032A1 (en) * 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
US8278104B2 (en) * 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
US8129187B2 (en) 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
US9213999B2 (en) * 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
JP2008307007A (ja) * 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
CN101855350B (zh) * 2008-05-02 2014-12-31 国立大学法人京都大学 核重编程序方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4975365A (en) * 1987-05-12 1990-12-04 The John Hopkins University Assay for measuring DNA cell repair potential
US5212057A (en) * 1988-10-26 1993-05-18 University Of Florida Biological system for constructing and testing viral vaccines
DE69233013T2 (de) * 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
FR2704234B1 (fr) * 1993-04-22 1995-07-21 Centre Nat Rech Scient Virus recombinants, preparation et utilisation en therapie genique.
RU2219241C2 (ru) * 1993-07-13 2003-12-20 Рон-Пуленк Роре С.А. Дефектный рекомбинантный аденовирусный вектор (варианты)

Also Published As

Publication number Publication date
NO973770L (no) 1997-10-15
CA2213116A1 (en) 1996-08-22
SK111397A3 (en) 1998-04-08
EP0811077B1 (en) 2004-11-24
PL182817B1 (pl) 2002-03-29
SK283027B6 (sk) 2003-02-04
ATE283371T1 (de) 2004-12-15
NZ303040A (en) 1998-07-28
AU700427B2 (en) 1999-01-07
UA45492C2 (uk) 2002-04-15
JPH11500012A (ja) 1999-01-06
KR19980702312A (ko) 1998-07-15
EP0811077A1 (en) 1997-12-10
HUP9802062A3 (en) 2001-08-28
AU4924896A (en) 1996-09-04
PL321869A1 (en) 1997-12-22
US5637456A (en) 1997-06-10
CZ257597A3 (cs) 1998-04-15
DE69633913D1 (de) 2004-12-30
WO1996025515A1 (en) 1996-08-22
BR9607613A (pt) 1999-11-30
NO973770D0 (no) 1997-08-15

Similar Documents

Publication Publication Date Title
HUP9802062A2 (hu) Gyors vizsgálati eljárás funkciónálisan inaktív gének mennyiségének meghatározására génterápiás vektorkészítményben
Boffa et al. Characterization of the gene encoding human TAFI (thrombin-activable fibrinolysis inhibitor; plasma procarboxypeptidase B)
Van Oostrum et al. Molecular composition of the adenovirus type 2 virion
Terakawa et al. Three types of mouse peptidylarginine deiminase: characterization and tissue distribution
Yamamoto et al. Heterogeneity of dystrophin-associated proteins
ATE213022T1 (de) Adenovirale vektoren für die gentherapie
Berkowitz et al. Epitope mapping of the von Willebrand factor subunit distinguishes fragments present in normal and type IIA von Willebrand disease from those generated by plasmin.
ITMI992519A1 (it) Proteine (iip) che interagiscono con il recettore igf-1 geni che le codificano e loro impiego
Glueck et al. Heterozygosity for the Leiden mutation of the factor V gene, a common pathoetiology for osteonecrosis of the jaw, with thrombophilia augmented by exogenous estrogens
DE69841164D1 (de) Sphingosin-1-phosphat-lyase polypeptide, polynukleotide und modulierende mitteln, und verfahren zu deren verwendung
Knudson et al. Distinct immunopeptide maps of the sarcoplasmic reticulum Ca2+ release channel in malignant hyperthermia.
Murata et al. Variant thyroxine-binding globulin in serum of Australian aborigines: its physical, chemical and biological properties
Yutani et al. Effect of amino acid residues on conformational stability in eight mutant proteins variously substituted at a unique position of the tryptophan synthase alpha-subunit.
Barbui et al. Subunits A and S inheritance in four families with congenital factor XIII deficiency
Kirchberger et al. Phospholamban: dissociation of the 22,000 molecular weight protein of cardiac sarcoplasmic reticulum into 11,000 and 5,500 molecular weight forms
Cheng et al. Transmembrane kit ligand cleavage does not require a signal in the cytoplasmic domain and occurs at a site dependent on spacing from the membrane.
Apple et al. Analyses of creatine kinase isoenzymes and isoforms in serum to detect reperfusion after acute myocardial infarction.
Gill et al. Microcalorimetric characterization of the anion-exchange adsorption of recombinant cytochrome b5 and its surface-charge mutants
Arnaud et al. The Pi system: its study by means of thin-layer-gel electrofocusing in polyacrylamide gel
Wallace et al. Visualization of protein—SDS complexes in polyacrylamide gels by chilling
Azim et al. Human erythrocyte dematin and protein 4.2 (pallidin) are ATP binding proteins
Sorrentino et al. Structural comparisons of fibronectins isolated from early and late passage cells
Williams et al. Characterization of an insulin receptor mutant lacking the subunit processing site.
Oka et al. Differential down-regulation of protein kinase C subspecies in normal human melanocytes: possible involvement of the ζ subspecies in growth regulation
Katz et al. Isoelectric heterogeneity of secreted renin differs after β-adrenergic stimulation